Anabolic steroids

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 2, Issue 3, 1999, Pages 243-253

  Creutzberg, Eva C ^a   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT;

ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; CLINICAL TRIAL; HUMAN; REVIEW; WASTING SYNDROME;

ACUTE DISEASE; ANABOLIC AGENTS; ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS; HUMANS; WASTING SYNDROME;

EID: 0033124922     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199905000-00008     Document Type: Article

References (43)

1. Hausmann DF, Nutz V, Rommelsheim K, Caspari R, Mosebach KO. Anabolic steroids in polytrauma patients. Influence on renal nitrogen and amino acid losses: a double-blind study. J Parenter Enter Nutr 1990; 14:111-114.
2. Hansell DT, Davies JW, Shenkin A, Garden OJ, Burns HJ, Carter DC. The effects of an anabolic steroid and peripherally administered intravenous nutrition in the early postoperative period. J Parenter Enter Nutr 1989; 13:349-358.
3. Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997; 43:47-51.
4. Chang DW, DeSanti L, Demling RH. Anticatabolic and anabolic strategies in critical illness: a review of current treatment modalities. Shock 1998; 10:155-160.
5. Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75:129-138.
6. Bhasin S, Storer TW, Asbel Sethi N, Kilbourne A, Hays R, Sinha Hikim I et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83:3155-3162.
7. Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3654-3662.
8. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11:41-45.
9. Schols A, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1791-1797.
10. Engelen M, Schols A, Heidendal GAK, Wouters EFM. Dual-energy X-ray absorptíometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 1998; 68:1298-1303.
11. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17:29-33.
12. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37:264-267.
13. Sturmi JE, Diorio DJ. Anabolic agents. Clin Sports Med 1998; 17:261-282.
14. Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Zamel N, Brooks D, Jardim JR. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28.
15. Bartsch W. Anabolic steroids - action on cellular level. Wien Med Wochenschr 1993; 143:363-366.
16. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469-3475.
17. Kuipers H, Peeze Binkhorst FM, Hartgens F, Wijnen JA, Keizer HA. Muscle ultrastructure after strength training with placebo or anabolic steroid. Can J Appl Physiol 1993; 18:189-196.
18. Bisschop A, Gayan Ramirez G, Rollier H, Dekhuijzen PNR, Dom R, DeBock V, Decramer M. Effects of nandrolone decanoate on respiratory and peripheral muscles in male and female rats. J Appl Physiol 1997; 82:1112-1118.
19. Prezant DJ, Karwa ML, Kim HH, Maggiore D, Chung V, Valentine DE. Short-and long-term effects of testosterone on diaphragm in castrated and normal male rats. J Appl Physiol 1997; 82:134-143.
20. Vanderschueren D, Boonen S. Androgen exposure and the maintenance of skeletal integrity in aging men. The Aging Male 1998; 1:180-187.
21. Eastell R, Boyle IT, Compston J, Cooper C, Fogelman I, Francis RM, et al. Management of male osteoporosis: report of the UK Consensus Group. Q J Med 1998; 91:71-92.
22. van Balkom RHH, Dekhuijzen PNR, Folgerging HTM, Veerkamp JH, van Moerkerk HT, Fransen JAM, van Herwaarden GLA. Anabolic steroids in part reverse glucocorticoid-induced alterations in rat diaphragm. J Appl Physiol 1998; 84:1492-1499.
23. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86:1200-1208.
24. Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition. Am J Gastroenterol 1991; 86:1209-1218.
25. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. J Parenter Enter Nutr 1995; 19:258-265.
26. Schols AMWJ, Soeters PB, Mostert R, Pluymers RJ, Wouters EFM. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152:1268-1274.
27. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7.
28. Mealy K, Clooney A, Marks P, Hennessy T, Jackson J. Effects of anabolic steroids on acute phase responses in intra-abdominal sepsis. Mediators Inflamm 1997; 6:69-72.
29. Hughes TK, Fulep E, Juelich T, Smith EM, Stanton GJ. Modulation of immune responses by anabolic androgenic steroids. Int J Immunopharmacol 1995; 17:857-863.
30. Drosos AA, van Vliet Dascalopoulou E, Andonopoulos AP, Galanopoulou V, Skopouli FN, Moutsopoulos HM. Nandrolone decanoate (deca-durabolin) in primary Sjogren's syndrome: a double blind pilot study. Clin Exp Rheumatol 1988; 6:53-57.
31. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10:1657-1662.
32. Gold J, High HA, Li Y, Michelmore H, Bodsworth NJ, Finlayson R, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996; 10:745-752.
33. Fenichel G, Pestronk A, Florence J, Robison V, Hemelt V. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 48:1225-1226.
34. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407-413.
35. Need AG, Nordin BE, Chatterton BE. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate. Osteoporos Int 1993; 3 (Suppl. 1):218-222.
36. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG. Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 1993; 17:211-219.
37. Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int 1997; 7:29-35.
38. Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JF. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30:495-500.
39. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther 1997; 19:383-404.
40. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3754-3758.
41. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Therapeutic perspective: issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998; 83:3435-3448.
42. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med 1991; 12:413-418.
43. Kouri EM, Pope Jr HG, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin J Sport Med 1996; 6:152-157.